JP2024501919A - フルマゼニルおよびナルトレキソンを含む組成物ならびにその使用方法 - Google Patents

フルマゼニルおよびナルトレキソンを含む組成物ならびにその使用方法 Download PDF

Info

Publication number
JP2024501919A
JP2024501919A JP2023532700A JP2023532700A JP2024501919A JP 2024501919 A JP2024501919 A JP 2024501919A JP 2023532700 A JP2023532700 A JP 2023532700A JP 2023532700 A JP2023532700 A JP 2023532700A JP 2024501919 A JP2024501919 A JP 2024501919A
Authority
JP
Japan
Prior art keywords
naltrexone
flumazenil
micrograms
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501919A5 (https=
Inventor
エリック ロドン，リー
ジョン ザナルド，ダニエル
チック，ジュリアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trexapharm Pty Ltd
Original Assignee
Trexapharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by Trexapharm Pty Ltd filed Critical Trexapharm Pty Ltd
Publication of JP2024501919A publication Critical patent/JP2024501919A/ja
Publication of JP2024501919A5 publication Critical patent/JP2024501919A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023532700A 2020-11-27 2021-11-26 フルマゼニルおよびナルトレキソンを含む組成物ならびにその使用方法 Pending JP2024501919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904390 2020-11-27
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof

Publications (2)

Publication Number Publication Date
JP2024501919A true JP2024501919A (ja) 2024-01-17
JP2024501919A5 JP2024501919A5 (https=) 2024-11-12

Family

ID=81753640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532700A Pending JP2024501919A (ja) 2020-11-27 2021-11-26 フルマゼニルおよびナルトレキソンを含む組成物ならびにその使用方法

Country Status (9)

Country Link
US (2) US12521401B2 (https=)
EP (1) EP4251168A4 (https=)
JP (1) JP2024501919A (https=)
KR (1) KR20230110793A9 (https=)
CN (2) CN116648246A (https=)
AU (2) AU2021388076B2 (https=)
CA (1) CA3201498A1 (https=)
IL (1) IL303117A (https=)
WO (1) WO2022109677A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535852A (ja) * 2005-04-07 2008-09-04 ハイシアム， インコーポレイテッド 不安関連障害の治療方法
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
JP2009543852A (ja) * 2006-07-14 2009-12-10 イバネーツ， ホアン ホセ レガルダ フルマゼニルの抑うつ障害の治療用医薬品の製造における使用
JP2016506933A (ja) * 2013-01-30 2016-03-07 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283212B2 (en) * 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008535852A (ja) * 2005-04-07 2008-09-04 ハイシアム， インコーポレイテッド 不安関連障害の治療方法
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
JP2009543852A (ja) * 2006-07-14 2009-12-10 イバネーツ， ホアン ホセ レガルダ フルマゼニルの抑うつ障害の治療用医薬品の製造における使用
JP2016506933A (ja) * 2013-01-30 2016-03-07 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same

Also Published As

Publication number Publication date
AU2021388076A9 (en) 2024-08-08
CN121695144A (zh) 2026-03-20
AU2021388076B2 (en) 2025-08-14
US20240000796A1 (en) 2024-01-04
WO2022109677A1 (en) 2022-06-02
EP4251168A1 (en) 2023-10-04
CN116648246A (zh) 2023-08-25
CA3201498A1 (en) 2022-06-02
IL303117A (en) 2023-07-01
EP4251168A4 (en) 2024-11-06
AU2025267401A1 (en) 2025-12-04
KR20230110793A (ko) 2023-07-25
US20260102405A1 (en) 2026-04-16
KR20230110793A9 (ko) 2024-11-13
US12521401B2 (en) 2026-01-13
AU2021388076A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
CA3086478A1 (en) Esketamine for the treatment of depression
JP6524110B2 (ja) 注射速度が増大したアリピプラゾール調合物
CN102133171A (zh) 延缓释放阿立哌唑的可注射组合物
CN108135865A (zh) 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
CN108348527A (zh) 用于治疗癫痫的方法
KR102063003B1 (ko) 비강내 저 용량 강도 테스토스테론 겔 제형 및 성불감증 또는 성욕 감퇴 장애를 치료하기 위한 이의 용도
US20260102405A1 (en) Compositions comprising flumazenil and naltrexone and methods for use thereof
WO2022086858A1 (en) Methods of treating post-traumatic stress disorder and related conditions
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
Golub et al. Potential consequences of high-dose infusion of ketamine for refractory status epilepticus: case reports and systematic literature review
JP2025161861A (ja) うつ病の処置
UA78199C2 (en) Use of flumazenil for preparing pharmaceutical composition for treating alcohol dependence
KR20210153059A (ko) 중수소화 덱스트로메토르판 및 퀴니딘을 사용하는 정신분열병의 음성 증상의 치료 방법
US20110195898A1 (en) Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists
EP2626065A1 (en) Compound composition for inhalation used for treating asthma
TW200422042A (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
RU2322238C2 (ru) Лечение ревматоидного артрита
CA3258070A1 (en) SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS INTENDED FOR USE IN THE TREATMENT OF DEPRESSIVE DISORDERS
JP6702883B2 (ja) 向神経活性ペプチドの安定な組成物
JP2020526500A (ja) 治療方法及びその剤形
US20170258815A1 (en) Corticosteroid formulations and methods for the treatment of joint pain in patients with diabetes
JPH07508036A (ja) タバコ禁断症候群を軽減するためへのコチニンの使用
US20240358693A1 (en) Methods of treating pain
CN101677978B (zh) 矫正骨吸收和骨形成失调的方法及其试剂盒和组合物
WO2025129263A1 (en) Treatment of breakthrough cancer pain

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317